Meanwhile, administration of FIS significantly reduced the incidence of MNU-induced bladder tumors by suppressing NF-κB activation and modulating the expression of NF-κB target genes, which regulate cell proliferation and apoptosis. This evidence concerns the gene NFKB1 and urinary bladder neoplasm.